Thymosin β4 promotes endothelial progenitor cell angiogenesis via a vascular endothelial growth factor‑dependent mechanism.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal experimental research with no human clinical data.
PubMed 29956769 · doi:10.3892/mmr.2018.9199
What was done
Researchers evaluated whether Thymosin β4 (Tβ4) enhances angiogenesis by promoting the paracrine secretion of endothelial progenitor cells (EPCs). In vitro, human umbilical vein endothelial cells (HUVECs) were cultured with conditioned medium from EPCs (EPC-CM) with or without Tβ4 pretreatment to measure tube formation and VEGF levels via ELISA, using a VEGF neutralizing antibody to test causality. Mechanistic involvement of the Akt/eNOS pathway was assessed using siRNA knockdown in EPCs. In vivo, Tβ4-pretreated EPCs versus untreated EPCs were transplanted into the border zones of infarcted rat hearts to evaluate local VEGF expression.
What was found
Tβ4 pretreatment of EPCs increased VEGF secretion into the conditioned medium. Tβ4-pretreated EPC-CM significantly promoted HUVEC tube formation compared to standard EPC-CM, an effect abolished by a VEGF neutralizing antibody. Knockdown of Akt or eNOS by siRNA significantly reduced VEGF expression in EPC-CM. In the rat myocardial infarction model, transplantation of Tβ4-pretreated EPCs produced significantly higher VEGF expression in the border zone compared to EPC transplantation alone. The abstract reports no exact numerical values or effect sizes.
Why it matters
The study outlines an Akt/eNOS- and VEGF-dependent paracrine mechanism by which Thymosin β4 enhances EPC-driven angiogenesis, highlighting a potential pretreatment strategy for optimizing EPCs used in ischemic cardiovascular therapies.
Limits
This is entirely preclinical research involving in vitro cell cultures and a rodent myocardial infarction model without direct human clinical data. The abstract provides no specific numerical data, sample sizes (n for cell replicates or rats), effect sizes, or functional cardiac endpoints (e.g., ejection fraction, scar size, or survival).
Cited by
- supports Certain regenerative peptides promote tissue healing and regeneration by upregulating vascular endothelial growth factor (VEGF).